Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences
24 March 2022 - 5:00PM
Geneva, Switzerland,
March
24,
2022 - Addex
Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage
pharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that CEO, Tim Dyer, will
present at both the Bio-Europe Spring 2022 Conference and the Maxim
Group – 2022 Virtual Growth Conference taking place March 28 - 31,
2022 and March 28 – 30, 2022, respectively. Dr. Robert Lütjens,
Head of Discovery – Biology, will also be attending the Bio-Europe
event.
In his presentation, Mr Dyer will provide a
corporate update and discuss recent developments at Addex. A video
of each presentation will be available for viewing on-demand by
registered participants.
Mr Dyer will be available for virtual one-on-one
meetings throughout both conferences. For more information or to
schedule a one-on-one meeting with management, please contact your
conference representative or IR@addexpharma.com.
About Addex
Therapeutics:Addex Therapeutics is a
clinical-stage pharmaceutical company focused on the development
and commercialization of an emerging class of novel orally
available small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is in a pivotal registration
clinical trial for Parkinson’s disease levodopa induced dyskinesia
(PD-LID) and has entered a Phase 2 clinical study for the treatment
of blepharospasm, a form of dystonia. Addex's third clinical
program, ADX71149 (mGlu2 positive allosteric modulator or PAM),
developed in collaboration with Janssen Pharmaceuticals, Inc., is
in a Phase 2a proof of concept clinical trial for the treatment of
epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for
the development of drug candidates with a focus in addiction.
Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for
PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for
Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Addex shares are listed on the SIX Swiss Exchange and American
Depositary Shares representing its shares are listed on the NASDAQ
Capital Market, and trade under the ticker symbol "ADXN" on each
exchange.
Contact:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
James
CarbonaraHayden IR(646)-755-7412james@haydenir.com |
Addex Forward Looking
Statements:This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including in respect of the
anticipated initiation of clinical trials. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in the Company’s Annual Report on Form 20-F filed with
the SEC on March 10, 2022, as well as market conditions and
regulatory review. Any forward-looking statements contained in this
press release represent Addex Therapeutics’ views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Addex Therapeutics explicitly disclaims
any obligation to update any forward-looking statements, except as
required by the law.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jul 2023 to Jul 2024